Clinical trials: fluorouracil
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
This single arm study will assess the efficacy and safety of a combination of modified FOLFIRI (irinotecan, 5-FU and leucovirin), Avastin and cetuximab in patients with previously untreated metastatic colorectal cancer.
- Trial name
- NCT00577109
- Testing
- bevacizumab [Avastin], Irinotecan, Leucovorin
- Where
- 3 sites in Brazil
- Sponsor
- Hoffmann-La Roche
Esophageal Neoplasms
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and 5-fluorouracil (5-FU) versus placebo plus SOC chemotherapy with cisplatin and 5-FU as…
- Trial name
- NCT03189719
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 189 sites in United States, Argentina and 24 more
- Volunteers
- 749 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
This is an open label, multicenter Phase Ib/II clinical study on the efficacy and safety of AK119 and AK112 in combination with or without chemotherapy, and AK112 monotherapy in pMMR/MSS CRC
- Trial name
- NCT05846867
- Testing
- AK119, AK112, Oxaliplatin
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Akeso
Advanced Solid Tumor
Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor
This study is a Phase I, open label, multi-center study of to evaluate the safety and efficacy of JMT101 in patients with advanced solid tumor.
- Trial name
- NCT04689100
- Testing
- JMT101
- Where
- 9 sites in China
- Volunteers
- 259 people
- Sponsor
- Shanghai JMT-Bio Inc.
Head and Neck Squamous Cell Carcinoma
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in participants with head and neck squamous cell…
- Trial name
- ELEVATE HNSCC (NCT04854499)
- Testing
- Magrolimab, Pembrolizumab, Docetaxel
- Where
- 88 sites in United States, Australia and 9 more
- Volunteers
- 193 people
- Sponsor
- Gilead Sciences
Locally Advanced or Metastatic Adenoca of the Biliary Tract
A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer
Multi-center, randomized Phase II study to evaluate the efficacy and safety of OSI-7904Lversus 5 FU/LV in biliary tract cancer.
- Trial name
- NCT00088270
- Testing
- OSI-7904L, 5-Fluorouracil/Leucovorin
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 58 people
- Sponsor
- OSI Pharmaceuticals
Colorectal Neoplasms, Liver Neoplasms
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
The study was terminated early due to low enrollment with only 2 subjects enrolled and treated after being open for enrollment for over a year. Therefore, no meaningful efficacy analyses could be performed.
- Trial name
- NCT00106054
- Testing
- Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Gastric Cancer
A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy of ipatasertib in combination with oxaliplatin, 5-fluorouracil, and leucovorin (modified FOLFOX6 [mFOLFOX6]) chemotherapy in…
- Trial name
- NCT01896531
- Testing
- 5-Fluorouracil, Ipatasertib, Leucovorin
- Where
- 34 sites in United States, France and 9 more
- Volunteers
- 153 people
- Sponsor
- Genentech, Inc.
Brainstem Glioma
A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas
This study evaluated the effect of capecitabine and concomitant radiation therapy in children with newly diagnosed brainstem gliomas.
- Trial name
- NCT01118377
- Testing
- Capecitabine, Radiation therapy
- Where
- 8 sites in United States
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Advanced Breast Cancer
Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer
This study is a randomized controlled study.The primary objective is to evaluate the Progression-Free Survival(PFS) of Utidelone Capsule combined with Capecitabine compared with Utidelone Injection combined with Capecitabine in…
- Trial name
- NCT07684456
- Testing
- Utidelone Capsule, Utidelone Injection, Capecitabine
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Gastrointestinal Tract Malignancies
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and…
- Trial name
- EDGE-Gastric (NCT05329766)
- Testing
- Domvanalimab, Quemliclustat, Zimberelimab
- Where
- 43 sites in United States, Canada and 4 more
- Volunteers
- 332 people
- Sponsor
- Arcus Biosciences, Inc.
Breast Cancer
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine…
- Trial name
- NCT05104866
- Testing
- Dato-DXd, Capecitabine, Gemcitabine
- Where
- 167 sites in United States, Argentina and 18 more
- Volunteers
- 732 people
- Sponsor
- AstraZeneca
Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
This study is a randomized, open-label, multicenter Phase II clinical study, with the objective to assess the efficacy and safety of JMT101 Injection combined with Mitoxantrone Hydrochloride Liposome Injection in patients with…
- Trial name
- NCT06892431
- Testing
- Mitoxantrone Hydrochloride Liposome, JMT101 injection, Capecitabine
- Volunteers
- 150 people
- Sponsor
- Shanghai JMT-Bio Inc.
Advanced Metastatic (Stage IV) Colorectal Cancer
A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer
The present trial is designed to determine whether pre-treatment with PledOx lowers the frequency and severity of side effects from FOLFOX6 administration in patients with metastatic colorectal cancer.
- Trial name
- PLIANT (NCT01619423)
- Testing
- PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg)
- Where
- 33 sites in United States, Bulgaria and 6 more
- Volunteers
- 186 people
- Sponsor
- Egetis Therapeutics AB (publ)
Head and Neck Cancer, Head and Neck Neoplasms
A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer
The primary objective of the first phase is to determine the safety, the maximum tolerated dose (MTD) and dose-limiting toxicity of TNFerade in combination with the previously studied combination of Fluorouracil (5FU)…
- Trial name
- NCT00496535
- Testing
- TNFerade biologic
- Where
- United States
- Sponsor
- GenVec
Colon Cancer
Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients
The aim of this study is to evaluate the synergistic anti-tumor effect of ChangTai Keli based on chemotherapy for colon cancer patients by a randomized, parallel-group, double-blind, multicenter clinical study.
- Trial name
- NCT02510118
- Testing
- mFOLFOX6, XELOX, ChangTai Keli
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Nanjing NingQi Medicine Science and Technology Co., Ltd.
Metastatic Colorectal Cancer
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
This was a randomized, placebo-controlled, double-blind study of vismodegib (GDC-0449) added to biochemotherapy standard-of-care regimens for metastatic colorectal cancer (CRC), with treatment until disease progression.
- Trial name
- NCT00636610
- Testing
- Vismodegib 150 mg, Bevacizumab, Modified FOLFOX
- Volunteers
- 199 people
- Sponsor
- Genentech, Inc.
Pancreatic Cancer
QUILT-3.080: NANT Pancreatic Cancer Vaccine
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care (SoC) chemotherapy.
- Trial name
- NCT03586869
- Testing
- Aldoxorubicin HCl, ALT-803, ETBX-011
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- ImmunityBio, Inc.
Metastatic Pancreatic Ductal Adenocarcinoma
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer.
- Trial name
- NCT05630183
- Testing
- Botensilimab, Gemcitabine, Nab-paclitaxel
- Where
- 36 sites in United States
- Volunteers
- 81 people
- Sponsor
- Agenus Inc.
Esophageal Cancer
Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer
The primary purpose of this study is to assess the safety and feasibility of giving TNFerade™ with 5-FU, Cisplatin and radiation therapy to patients with locally advanced, esophageal cancer prior to surgical resection.
- Trial name
- NCT00051480
- Testing
- TNFerade
- Where
- 12 sites in United States
- Sponsor
- GenVec